How big is INVO BioScience, Inc.?

As of Jun 18, INVO BioScience, Inc. has a market capitalization of 2.70 million, with net sales of 6.60 million and a net profit of -24.90 million over the last four quarters. The company's shareholder's funds are 12.75 million, and total assets amount to 46.45 million.

Market Cap: As of Jun 18, INVO BioScience, Inc. has a market capitalization of 2.70 million, which categorizes it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 6.60 million and a net profit of -24.90 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 12.75 million, while total assets were reported at 46.45 million.

What does INVO BioScience, Inc. do?

INVO BioScience, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $17 million as of March 2025. It has a market cap of $2.70 million and key metrics indicate a negative return on equity and no dividend yield.

Overview: INVO BioScience, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025). Market cap: USD 2.70 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: 0.80. Return on Equity: -139.69%. Price to Book: 0.37.<BR><BR>Contact Details: No Company Details Available. Registrar Address: Not available.

Should I buy, sell or hold INVO BioScience, Inc.?

Is INVO BioScience, Inc. overvalued or undervalued?

As of May 15, 2023, INVO BioScience, Inc. is considered risky and overvalued due to significant losses, reflected in poor valuation metrics and a year-to-date stock performance decline of 97.01%, contrasting sharply with the S&P 500's positive return.

As of 15 May 2023, the valuation grade for INVO BioScience, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses, as evidenced by a Price to Book Value of 0.13, an EV to EBIT of -0.75, and an EV to EBITDA of -0.83. In comparison to peers, NanoVibronix, Inc. has a more pronounced EV to EBITDA of -0.2892, while Nuwellis, Inc. shows an EV to EBIT of -0.2109, suggesting that INVO BioScience is lagging behind its competitors in terms of valuation metrics.<BR><BR>Furthermore, the company's stock performance has been dismal, with a year-to-date return of -97.01%, starkly contrasting with the S&P 500's positive return of 12.22% during the same period. This dramatic underperformance reinforces the notion that INVO BioScience is overvalued in its current state.

Is INVO BioScience, Inc. technically bullish or bearish?

As of August 26, 2025, INVO BioScience, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and Bollinger Bands, despite mildly bullish weekly and monthly MACD readings, and has underperformed the S&P 500 with a year-to-date return of -97.01%.

As of 26 August 2025, the technical trend for INVO BioScience, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the Bollinger Bands, both reflecting bearish signals. The weekly and monthly MACD readings are mildly bullish, but they are overshadowed by the bearish signals from the KST and Dow Theory on a monthly basis. The stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -97.01% versus the S&P 500's 12.22%.